Communications about Ongoing Safety Reviews

• Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR) (8/28/2009)
• Follow-up to the June 4, 2008 Early Communication about the Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, Cimzia, and Simponi) (8/4/2009)
• Update of Safety Review of OnabotulinumtoxinA (marketed as Botox/Botox Cosmetic), AbobotulinumtoxinA (marketed as Dysport) and RimabotulinumtoxinB (marketed as Myobloc) (8/3/2009)
• Communication about Cefepime (marketed as Maxipime) Safety Review: An Update (6/17/2009)
• Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR) (6/12/2009)
• Communication about an Ongoing Safety Review of Stimulant Medications used in Children with Attention-Deficit/Hyperactivity Disorder (ADHD) (6/23/2009)
• Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor) (1/8/2009)
• Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Montelukast (Singulair) (1/13/2009)
• Communication about an Ongoing Safety Review of Innohep (tinzaparin sodium injection) (12/2/2008)
• Communication About an Ongoing Safety Review of CellCept (mycophenolate mofetil) and Myfortic (mycophenolic acid) (4/10/2008)
• Communication about an Ongoing Safety Review on Erythropoiesis-Stimulating Agents (ESAs) Epoetin alfa (marketed as Procrit, Epogen) Darbepoetin alfa (marketed as Aranesp) (1/3/2008)
• Update of Safety Review: Follow-up to the November 14, 2007, Communication about the Ongoing Safety Review of Cefepime (marketed as Maxipime) (5/14/2008)
• Update of Safety Review: Follow-up to the August 9, 2007, Communication about the Ongoing Safety Review of Omeprazole and Esomeprazole (12/10/2007)
• Communication about an Ongoing Safety Review of Regranex (becaplermin)
• Update of Safety Review: Follow-up to the March 27, 2008, Communication about the Ongoing Safety Review of Regranex (becaplermin)